No significant differences were detected between patients who continued and stopped luma/iva treatment; however, levels of IL-8 and NE in both subgroups analyzed separately or combined (all CF patients) were significantly greater than measured in non-CF controls. The gene discussed is CXCL8; the disease is cystic fibrosis.